-
NMPA Issued the Announcement on Cancellation of 68 Certification Items (Third Batch)
2019-11-29
NMPA decided to cancel 68 certification items (attachment, omitted) and issued an Announcement on November 29, 2019.
-
NMPA Issued the Technical Guidelines for Aluminum-Adjuvant-containing Preventive Vaccines
2019-12-10
NMPA has organized the formulation of the Technical Guidelines for Aluminum-Adjuvant-containing Preventive Vaccines, which has been released on December 10, 2019.
-
NMPA Issued the Technical Guidelines for Clinical Comparability Exercise of Preventive Vaccines
2019-12-24
To further standardize and improve the clinical R&D of vaccines and strengthen the supervision of vaccine quality and safety, NMPA has organized the formulation of the Technical Guidelines for Clinical Comparability Exercise of Preventive Vaccines, which has been released on December 24, 2019.
-
NMPA Issued the Guidelines for Adverse Event Classification Standards for Clinical Trials of Preventive Vaccines
2019-12-31
NMPA has organized the drafting of and released on December 31, 2019 the Guidelines for Adverse Event Classification Standards for Clinical Trials of Preventive Vaccines.
-
NMPA Issued the Announcement on the Guidelines for Real-World Evidence to Support Drug Development and Review (Interim)
2020-01-07
NMPA has organized the formulation of the Guidelines for Real-World Evidence to Support Drug Development and Review (Interim).
-
NMPA Issued the Guidelines for Clinical Trials of Drugs for Treatment of Nonalcoholic Steatohepatitis (Interim)
2019-12-20
NMPA has organized the formulation of the Guidelines for Clinical Trials of Drugs for Treatment of Nonalcoholic Steatohepatitis (Interim), which was released on December 20, 2019.
